Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Common Equity (2016 - 2025)

Historic Common Equity for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $455.1 million.

  • Spyre Therapeutics' Common Equity rose 3900.85% to $455.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.1 million, marking a year-over-year increase of 3900.85%. This contributed to the annual value of $517.8 million for FY2024, which is 18139.07% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Common Equity stood at $455.1 million, which was up 3900.85% from $455.8 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Common Equity peaked at $517.8 million during Q4 2024, and registered a low of -$245.4 million during Q3 2023.
  • For the 5-year period, Spyre Therapeutics' Common Equity averaged around $169.6 million, with its median value being $119.0 million (2021).
  • Per our database at Business Quant, Spyre Therapeutics' Common Equity tumbled by 46326.25% in 2023 and then skyrocketed by 35248.13% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Common Equity stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then surged by 265.8% to $184.0 million in 2023, then surged by 181.39% to $517.8 million in 2024, then fell by 12.11% to $455.1 million in 2025.
  • Its Common Equity stands at $455.1 million for Q3 2025, versus $455.8 million for Q2 2025 and $482.6 million for Q1 2025.